You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlanzapine
Accession NumberDB00334  (APRD00138)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.

Structure
Thumb
Synonyms
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Olanzapin
Olanzapina
Olanzapine
Olanzapinum
Zyprexa
External Identifiers
  • LY 170053
  • UNII-X7S6Q4MHCB
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-olanzapine ODTtablet (orally disintegrating)5 mgoralBgp Pharma Ulc2014-09-172015-12-31Canada
Abbott-olanzapine ODTtablet (orally disintegrating)15 mgoralAbbott Laboratories2014-12-032015-12-31Canada
Abbott-olanzapine ODTtablet (orally disintegrating)10 mgoralAbbott Laboratories, Limited2014-09-172015-12-31Canada
Accel-olanzapinetablet20 mgoralAccel Pharma IncNot applicableNot applicableCanada
Accel-olanzapinetablet15 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet10 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet7.5 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet5 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet2.5 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Act Olanzapinetablet2.5 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet20 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet15 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet10 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet7.5 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet5 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)15 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)10 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)5 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)20 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)20 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)15 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)10 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)5 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Ava-olanzapinetablet15.0 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet10.0 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet7.5 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet5.0 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet2.5 mgoralAvanstra Inc2011-11-232014-08-21Canada
Dom-olanzapinetablet15 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet10 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet7.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet2.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTtablet (orally disintegrating)15 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTtablet (orally disintegrating)10 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTtablet (orally disintegrating)5 mgoralDominion PharmacalNot applicableNot applicableCanada
Ipg-olanzapinetablet7.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet2.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp Olanzapine Fctablet20 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet15 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet10 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet7.5 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet5 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet2.5 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)20 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)15 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)10 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)5 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Mar-olanzapinetablet2.5 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet5 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-olanzapinetablet15 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet10 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet7.5 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)15 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)20 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)10 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)5 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mint-olanzapinetablet20 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet15 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet10 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet7.5 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet5 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet2.5 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)20 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)15 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)10 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)5 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mylan-olanzapinetablet20 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet15 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet10 mgoralMylan Pharmaceuticals Ulc2010-05-16Not applicableCanada
Mylan-olanzapinetablet7.5 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet5 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet2.5 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)20 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)15 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)10 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)5 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Ntp-olanzapinetablet2.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet15.0 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet10.0 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet7.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet5.0 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-olanzapinetablet2.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet15.0 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet10.0 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet7.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet5.0 mgoralNu Pharm IncNot applicableNot applicableCanada
Olanzapinetablet15 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet20 mgoralPro Doc Limitee2014-06-10Not applicableCanada
Olanzapinetablet10 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet10 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet15 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet7.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet2.5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet15 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet10 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet7.5 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet7.5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet5 mg/1oralREMEDYREPACK INC.2013-04-29Not applicableUs
Olanzapinetablet5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet10 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet5 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-07-22Not applicableUs
Olanzapinetablet20 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Olanzapinetablet2.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet7.5 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet7.5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet15 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet2.5 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet2.5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet20 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet5 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet15 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet2.5 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet2.5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet10 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet7.5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet15 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet7.5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet15 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet2.5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine for Injectionpowder for solution10 mgintramuscularSandoz Canada Incorporated2014-07-22Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)15 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)20 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)10 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)20 mgoralSanis Health IncNot applicableNot applicableCanada
Olanzapine ODTtablet (orally disintegrating)15 mgoralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)15 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine ODTtablet (orally disintegrating)15 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)10 mgoralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)10 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine ODTtablet (orally disintegrating)10 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)20 mgoralPro Doc Limitee2014-06-10Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine-odttablet (orally disintegrating)20 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odttablet (orally disintegrating)15 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odttablet (orally disintegrating)10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odttablet (orally disintegrating)5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
PHL-olanzapinetablet2.5 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet5 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet15 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet10 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet7.5 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapine ODTtablet (orally disintegrating)15 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapine ODTtablet (orally disintegrating)10 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapine ODTtablet (orally disintegrating)5 mgoralPharmel Inc2010-02-18Not applicableCanada
PMS-olanzapinetablet2.5 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet20 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-olanzapinetablet15 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet10 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet7.5 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet5 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)20 mgoralPharmascience Inc2014-07-29Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)15 mgoralPharmascience Inc2009-10-15Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)10 mgoralPharmascience Inc2009-10-15Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)5 mgoralPharmascience Inc2009-10-15Not applicableCanada
Ran-olanzapinetablet15.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet10.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet7.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet5.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapine Irtablet5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet7.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet15 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)15 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)10 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)5 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)20 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Riva-olanzapinetablet7.5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet10 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet2.5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet15 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)15 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)10 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)20 mgoralLaboratoire Riva Inc2014-06-12Not applicableCanada
Sandoz Olanzapinetablet5.0 mgoralSandoz Canada Incorporated2009-12-06Not applicableCanada
Sandoz Olanzapinetablet2.5 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapinetablet20.0 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Olanzapinetablet15.0 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapinetablet10.0 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapinetablet7.5 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)20 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)15 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)10 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)5 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Teva-olanzapinetablet15 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet10 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet7.5 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet5 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet20 mgoralTeva Canada Limited2011-04-28Not applicableCanada
Teva-olanzapinetablet2.5 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapine ODtablet (orally disintegrating)20 mgoralTeva Canada Limited2010-03-082016-01-18Canada
Teva-olanzapine ODtablet (orally disintegrating)15 mgoralTeva Canada Limited2010-03-082016-01-18Canada
Teva-olanzapine ODTtablet (orally disintegrating)5 mgoralTeva Canada Limited2010-03-08Not applicableCanada
Teva-olanzapine ODTtablet (orally disintegrating)10 mgoralTeva Canada Limited2010-03-08Not applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)10 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)15 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)5 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)20 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-olanzapinetablet15 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet10 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet7.5 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet5.0 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet2.5 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)5 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)20 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)15 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)10 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Zyprexatablet15 mg/1oralDispensing Solutions, Inc.2000-01-10Not applicableUs
Zyprexatablet10 mg/1oralRebel Distributors Corp1996-10-01Not applicableUs
Zyprexatablet2.5 mg/1oralEli Lilly and Company1997-06-23Not applicableUs
Zyprexatablet10 mg/1oralCardinal Health1996-10-01Not applicableUs
Zyprexatablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs
Zyprexatablet20 mg/1oralRebel Distributors Corp2001-03-01Not applicableUs
Zyprexatablet5 mg/1oralRebel Distributors Corp1996-10-01Not applicableUs
Zyprexatablet5 mg/1oralCardinal Health1996-10-01Not applicableUs
Zyprexatablet10 mg/1oralDispensing Solutions, Inc.1996-10-01Not applicableUs
Zyprexatablet7.5 mg/1oralPhysicians Total Care, Inc.2005-06-14Not applicableUs
Zyprexatablet5 mg/1oralDispensing Solutions, Inc.1996-10-01Not applicableUs
Zyprexatablet5 mg/1oralSTAT Rx USA LLC1996-10-01Not applicableUs
Zyprexatablet2.5 mg/1oralPhysicians Total Care, Inc.2003-08-20Not applicableUs
Zyprexatablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-07-12Not applicableUs
Zyprexatablet2.5 mg/1oralDispensing Solutions, Inc.1997-06-23Not applicableUs
Zyprexatablet20 mg/1oralEli Lilly and Company2001-03-01Not applicableUs
Zyprexatablet5 mg/1oralPhysicians Total Care, Inc.2003-09-30Not applicableUs
Zyprexatablet20 mg/1oralREMEDYREPACK INC.2013-07-082016-04-05Us
Zyprexatablet2.5 mg/1oralbryant ranch prepack1997-06-23Not applicableUs
Zyprexatablet15 mg/1oralEli Lilly and Company2000-01-10Not applicableUs
Zyprexatablet10 mg/1oralPd Rx Pharmaceuticals, Inc.1996-10-01Not applicableUs
Zyprexatablet10 mg/1oralEli Lilly and Company1996-10-01Not applicableUs
Zyprexatablet10 mg/1oralPhysicians Total Care, Inc.2003-06-20Not applicableUs
Zyprexatablet15 mg/1oralREMEDYREPACK INC.2013-05-142016-04-05Us
Zyprexatablet2.5 mg/1oralCardinal Health1997-06-23Not applicableUs
Zyprexatablet7.5 mg/1oralEli Lilly and Company1996-10-01Not applicableUs
Zyprexatablet2.5 mg/1oralH.J. Harkins Company, Inc.1997-06-23Not applicableUs
Zyprexatablet5 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
Zyprexatablet5 mg/1oralEli Lilly and Company1996-10-01Not applicableUs
Zyprexatablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs
Zyprexatablet10 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
Zyprexa -2.5mgtablet2.5 mgoralEli Lilly Canada Inc1997-12-08Not applicableCanada
Zyprexa -7.5mgtablet7.5 mgoralEli Lilly Canada Inc1996-11-04Not applicableCanada
Zyprexa - 10mgtablet10 mgoralEli Lilly Canada Inc1996-11-14Not applicableCanada
Zyprexa - 5mgtablet5 mgoralEli Lilly Canada Inc1996-11-14Not applicableCanada
Zyprexa 15mgtablet15 mgoralEli Lilly Canada Inc2002-06-24Not applicableCanada
Zyprexa 20mgtablet20 mgoralEli Lilly Canada Inc2007-04-30Not applicableCanada
Zyprexa Intramuscularpowder for solution10 mgintramuscularEli Lilly Canada Inc2004-01-12Not applicableCanada
Zyprexa Intramuscularinjection, powder, for solution10 mg/2mLintramuscularEli Lilly and Company2004-04-01Not applicableUs
Zyprexa RelprevvkitintramuscularEli Lilly and Company2010-03-01Not applicableUs
Zyprexa RelprevvkitintramuscularEli Lilly and Company2010-03-01Not applicableUs
Zyprexa RelprevvkitintramuscularEli Lilly and Company2010-03-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)10 mgoralEli Lilly Canada Inc2001-03-15Not applicableCanada
Zyprexa Zydistablet, orally disintegrating10 mg/1oralCardinal Health2000-06-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)15 mgoralEli Lilly Canada Inc2004-01-09Not applicableCanada
Zyprexa Zydistablet, orally disintegrating15 mg/1oralEli Lilly and Company2001-09-01Not applicableUs
Zyprexa Zydistablet, orally disintegrating10 mg/1oralEli Lilly and Company2000-06-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)5 mgoralEli Lilly Canada Inc2001-03-06Not applicableCanada
Zyprexa Zydistablet, orally disintegrating5 mg/1oralEli Lilly and Company2000-06-01Not applicableUs
Zyprexa Zydistablet, orally disintegrating5 mg/1oralCardinal Health2000-06-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)20 mgoralEli Lilly Canada Inc2007-01-02Not applicableCanada
Zyprexa Zydistablet, orally disintegrating20 mg/1oralEli Lilly and Company2001-09-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olanzapinetablet5.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet2.5 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet20.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet15.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet10.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet7.5 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)20 mgoralApotex Inc2011-08-08Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)15 mgoralApotex Inc2011-08-08Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)10 mgoralApotex Inc2011-08-08Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)5 mgoralApotex Inc2011-11-16Not applicableCanada
Olanzapinetablet, film coated20 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralREMEDYREPACK INC.2015-05-26Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralCardinal Health2012-02-17Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet2.5 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet2.5 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-08-06Not applicableUs
Olanzapinetablet5 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet5 mg/1oralTYA Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet20 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet15 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet5 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralREMEDYREPACK INC.2014-02-06Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralCardinal Health2012-02-17Not applicableUs
Olanzapinetablet, film coated20 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, orally disintegrating15 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, film coated5 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralPhysicians Total Care, Inc.2012-07-02Not applicableUs
Olanzapinetablet20 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet2.5 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet2.5 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2012-12-13Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-10-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2015-12-30Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet, film coated5 mg/1oralTYA Pharmaceuticals2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTYA Pharmaceuticals2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet15 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet10 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2014-02-03Not applicableUs
Olanzapinetablet20 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2013-04-22Not applicableUs
Olanzapinetablet, film coated10 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, orally disintegrating10 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAvera Mc Kennan Hospital2015-09-02Not applicableUs
Olanzapinetablet, film coated15 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet, film coated20 mg/1oralREMEDYREPACK INC.2014-08-07Not applicableUs
Olanzapineinjection, powder, for solution10 mg/2mLintramuscularTYA Pharmaceuticals2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralbryant ranch prepack2011-10-24Not applicableUs
Olanzapinetablet20 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet10 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet7.5 mg/1oralAscend Laboratories, LLC2012-01-02Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-01-212016-04-05Us
Olanzapinetablet15 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
Olanzapinetablet, film coated5 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, orally disintegrating5 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet, film coated5 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapineinjection, powder, lyophilized, for solution10 mg/2mLintramuscularAmerican Regent, Inc.2012-06-27Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralREMEDYREPACK INC.2016-01-07Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet20 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, film coated10 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2014-08-07Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-12-30Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet7.5 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet5 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet5 mg/1oralREMEDYREPACK INC.2013-04-01Not applicableUs
Olanzapinetablet10 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
Olanzapinetablet, film coated10 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, film coated20 mg/1oralDr.Reddy's laboratories Ltd.2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralAmerican Health Packaging2014-05-01Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet20 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet, film coated2.5 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet, film coated20 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet20 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapineinjection, powder, lyophilized, for solution10 mg/2mLintramuscularTYA Pharmaceuticals2012-06-27Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralProficient Rx LP2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTeva Pharmaceuticals USA Inc2012-01-24Not applicableUs
Olanzapinetablet15 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapineinjection, powder, for solution10 mg/2mLintramuscularSandoz Inc2011-10-24Not applicableUs
Olanzapinetablet10 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, film coated5 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet, film coated15 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-11-20Not applicableUs
Olanzapinetablet20 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTYA Pharmaceuticals2012-02-28Not applicableUs
Olanzapinetablet, film coated10 mg/1oralProficient Rx LP2012-04-23Not applicableUs
Olanzapinetablet10 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet20 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet5 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet2.5 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-03-28Not applicableUs
Olanzapinetablet7.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralCardinal Health2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, film coated15 mg/1oralDr.Reddy's laboratories Ltd.2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralAmerican Health Packaging2014-05-01Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet, film coated10 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet10 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-11-17Not applicableUs
Olanzapinetablet15 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralTYA Pharmaceuticals2012-02-28Not applicableUs
Olanzapinetablet, film coated5 mg/1oralProficient Rx LP2014-08-22Not applicableUs
Olanzapinetablet7.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet2.5 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-01-04Not applicableUs
Olanzapinetablet5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralAvera Mc Kennan Hospital2015-04-22Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralDr.Reddy's Laboratories Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralAmerican Health Packaging2012-02-01Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralTeva Pharmaceuticals USA Inc2012-01-24Not applicableUs
Olanzapinetablet10 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapineinjection, powder, for solution10 mg/2mLintramuscularSandoz Inc2011-10-24Not applicableUs
Olanzapinetablet7.5 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet, film coated20 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet7.5 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet20 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs
Olanzapinetablet10 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralTYA Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralProficient Rx LP2011-10-24Not applicableUs
Olanzapinetablet5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet10 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-06-05Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet5 mg/1oralREMEDYREPACK INC.2013-04-01Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-03-29Not applicableUs
Olanzapinetablet2.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, film coated5 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2012-08-22Not applicableUs
Olanzapinetablet, film coated15 mg/1oralAmerican Health Packaging2012-02-01Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralTeva Pharmaceuticals USA Inc2012-02-17Not applicableUs
Olanzapinetablet7.5 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet, film coated15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet5 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet, film coated10 mg/1oralClinical Solutions Wholesale, Llc2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, film coated5 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet5 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs
Olanzapinetablet7.5 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet10 mg/1oralTYA Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralProficient Rx LP2011-10-24Not applicableUs
Olanzapinetablet2.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet7.5 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2014-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-04-01Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, film coated10 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralPhysicians Total Care, Inc.2012-08-22Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Olanzapinetablet, film coated15 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated20 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralTeva Pharmaceuticals USA Inc2012-02-17Not applicableUs
Olanzapinetablet5 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet2.5 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AedonG.L. Pharma
AmulsinSanitas
ApiscoLKM
ApsicoLKM
ArkolamylMylan
CaprilonLavipharm
CO OlanzapineCobalt
DeprexSquare
DominazolStein
DopinDaksh
EgolanzaEGIS
ElynzaElynza
FrenialBiogen
Jolyon-MDLupin
KozylexQuisisana
LanopinMolekule
LanzapinBiogened
LanzepRenata
LapenzaSmart Intermed
LapozanMedochemie
LazapixPortfarma
Brand mixtures
NameLabellerIngredients
Olanzapine and FluoxetineTeva Pharmaceuticals USA Inc
SymbyaxEli Lilly and Company
Salts
Name/CASStructureProperties
Olanzapine pamoate
ThumbNot applicableDBSALT001064
Categories
UNIIN7U69T4SZR
CAS number132539-06-1
WeightAverage: 312.432
Monoisotopic: 312.14086735
Chemical FormulaC17H20N4S
InChI KeyInChIKey=KVWDHTXUZHCGIO-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
IUPAC Name
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub ClassNot Available
Direct ParentBenzodiazepines
Alternative Parents
Substituents
  • Benzodiazepine
  • Thieno-para-diazepine
  • 2,3,5-trisubstituted thiophene
  • N-alkylpiperazine
  • N-methylpiperazine
  • Para-diazepine
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients.
PharmacodynamicsOlanzapine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, olanzapine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.
Mechanism of actionOlanzapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Related Articles
AbsorptionWell absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.
Volume of distribution
  • 1000 L
Protein binding93%
Metabolism

Hepatic

SubstrateEnzymesProduct
Olanzapine
7-hydroxyolanzapineDetails
Olanzapine
4'-N-desmethylolanzapineDetails
Olanzapine
2-hydroxymethylolanzapineDetails
Route of eliminationIt is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. Following a single oral dose of 14C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized.
Half life21 to 54 hours
Clearance
  • 12 to 47 L/h
ToxicitySymptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 0.45g, but also survival after an acute overdose of 1500g.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableCC Allele (homozygous)Associated with the ability to ameliorate impaired attention in patients with schizophrenia.20533011
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.9652
Caco-2 permeable+0.5993
P-glycoprotein substrateSubstrate0.8524
P-glycoprotein inhibitor IInhibitor0.6888
P-glycoprotein inhibitor IIInhibitor0.7204
Renal organic cation transporterInhibitor0.7715
CYP450 2C9 substrateNon-substrate0.7493
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5421
CYP450 1A2 substrateInhibitor0.6454
CYP450 2C9 inhibitorNon-inhibitor0.6914
CYP450 2D6 inhibitorInhibitor0.608
CYP450 2C19 inhibitorInhibitor0.572
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.707
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.9369
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.7569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Tabletoral10.0 mg
Tabletoral15.0 mg
Tabletoral20.0 mg
Tabletoral5.0 mg
Injection, powder, lyophilized, for solutionintramuscular10 mg/2mL
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral2.5 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral5 mg/1
Tablet, film coatedoral7.5 mg/1
Capsuleoral
Tabletoral10 mg/1
Tabletoral15 mg/1
Tabletoral2.5 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Tabletoral7.5 mg/1
Tabletoral2.5 mg
Tabletoral7.5 mg
Tabletoral10 mg
Tabletoral5 mg
Tabletoral15 mg
Tabletoral20 mg
Injection, powder, for solutionintramuscular10 mg/2mL
Powder for solutionintramuscular10 mg
Kitintramuscular
Tablet (orally disintegrating)oral10 mg
Tablet (orally disintegrating)oral15 mg
Tablet (orally disintegrating)oral20 mg
Tablet (orally disintegrating)oral5 mg
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral20 mg/1
Tablet, orally disintegratingoral5 mg/1
Prices
Unit descriptionCostUnit
Zyprexa relprevv 405 mg vial1287.9USD vial
Zyprexa relprevv 300 mg vial954.0USD vial
Zyprexa relprevv 210 mg vial667.8USD vial
ZyPREXA Zydis 30 10 mg Dispersible Tablet Box562.35USD box
ZyPREXA Zydis 30 5 mg Dispersible Tablet Box385.63USD box
Zyprexa 10 mg vial35.69USD vial
Zyprexa zydis 20 mg tablet34.87USD tablet
Zyprexa 20 mg tablet34.37USD tablet
Zyprexa zydis 15 mg tablet26.45USD tablet
Zyprexa 15 mg tablet21.14USD tablet
Symbyax 12-25 mg capsule20.62USD capsule
Symbyax 12-50 mg capsule20.62USD capsule
Zyprexa zydis 10 mg tablet18.02USD tablet
Symbyax 6-50 mg capsule14.56USD capsule
Zyprexa 10 mg tablet14.09USD tablet
Symbyax 6-25 mg capsule13.69USD capsule
Zyprexa zydis 5 mg tablet12.36USD tablet
Zyprexa 7.5 mg tablet11.23USD tablet
Symbyax 3-25 mg capsule10.01USD capsule
Zyprexa 5 mg tablet8.92USD tablet
Zyprexa Zydis 10 mg Disintegrating Tablet7.86USD tablet
Zyprexa 2.5 mg tablet7.1USD tablet
Apo-Olanzapine 15 mg Tablet6.64USD tablet
Co Olanzapine 15 mg Tablet6.64USD tablet
Novo-Olanzapine 15 mg Tablet6.64USD tablet
Pms-Olanzapine 15 mg Tablet6.64USD tablet
Apo-Olanzapine 10 mg Tablet4.43USD tablet
Co Olanzapine 10 mg Tablet4.43USD tablet
Novo-Olanzapine 10 mg Tablet4.43USD tablet
Pms-Olanzapine 10 mg Tablet4.43USD tablet
Zyprexa Zydis 5 mg Disintegrating Tablet3.93USD tablet
Co Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Novo-Olanzapine Od 10 mg Disintegrating Tablet3.54USD tablet
Pms-Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Sandoz Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Apo-Olanzapine 7.5 mg Tablet3.32USD tablet
Co Olanzapine 7.5 mg Tablet3.32USD tablet
Novo-Olanzapine 7.5 mg Tablet3.32USD tablet
Pms-Olanzapine 7.5 mg Tablet3.32USD tablet
Apo-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine 5 mg Tablet2.21USD tablet
Novo-Olanzapine 5 mg Tablet2.21USD tablet
Pms-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Novo-Olanzapine Od 5 mg Disintegrating Tablet1.77USD tablet
Pms-Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Sandoz Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Apo-Olanzapine 2.5 mg Tablet1.11USD tablet
Co Olanzapine 2.5 mg Tablet1.11USD tablet
Novo-Olanzapine 2.5 mg Tablet1.11USD tablet
Pms-Olanzapine 2.5 mg Tablet1.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2041113 No1998-07-142011-04-24Canada
CA2216372 No2007-11-202016-03-22Canada
US5229382 No1994-04-232011-04-23Us
US5945416 No1997-03-242017-03-24Us
US6169084 No1998-09-302018-09-30Us
US6251895 No1998-03-232018-03-23Us
US6960577 No1997-11-012017-11-01Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195 °CNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0942 mg/mLALOGPS
logP3.61ALOGPS
logP3.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.17ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity93.87 m3·mol-1ChemAxon
Polarizability35.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Charles Arthur Bunnell, Samuel Dean Larsen, John Richard Nichols, Susan Marie Reutzel, Gregory Alan Stephenson, “Intermediates and process for preparing olanzapine.” U.S. Patent US6020487, issued September, 1996.

US6020487
General References
  1. de Haan L, van Amelsvoort T, Rosien K, Linszen D: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl). 2004 Sep;175(3):389-90. [PubMed:15322727 ]
  2. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 1;59(3):211-5. Epub 2005 Sep 1. [PubMed:16139813 ]
  3. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 Feb;26(1):45-9. [PubMed:16415705 ]
  4. Jakovljevic M, Sagud M, Mihaljevic-Peles A: Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. Acta Psychiatr Scand. 2003 May;107(5):394-6; discussion 396. [PubMed:12752037 ]
  5. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 1;61(1):7-18. [PubMed:12648731 ]
External Links
ATC CodesN05AH03
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (251 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Olanzapine can be increased when it is combined with Abiraterone.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine.
AclidiniumAclidinium may increase the anticholinergic activities of Olanzapine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine.
AlprazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alprazolam.
AmisulprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olanzapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Olanzapine.
AmphetamineOlanzapine may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Olanzapine.
AzelastineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Olanzapine.
BenzphetamineOlanzapine may decrease the stimulatory activities of Benzphetamine.
BortezomibThe metabolism of Olanzapine can be decreased when combined with Bortezomib.
Botulinum Toxin Type AOlanzapine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BOlanzapine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
BromazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromazepam.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Olanzapine.
BuprenorphineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Olanzapine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Olanzapine.
CamazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Camazepam.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.
CarbamazepineThe metabolism of Olanzapine can be increased when combined with Carbamazepine.
CathinoneOlanzapine may decrease the stimulatory activities of Cathinone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlormezanone.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Olanzapine.
Cimetropium BromideOlanzapine may increase the anticholinergic activities of Cimetropium Bromide.
CinolazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cinolazepam.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Olanzapine.
ClobazamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clobazam.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Olanzapine.
ClonazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonazepam.
ClorazepateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clorazepate.
ClotiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clotiazepam.
CloxazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cloxazolam.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olanzapine.
Cyproterone acetateThe serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate.
DeferasiroxThe serum concentration of Olanzapine can be increased when it is combined with Deferasirox.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Olanzapine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Olanzapine.
DextroamphetamineOlanzapine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Olanzapine.
DiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diazepam.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Olanzapine.
DofetilideOlanzapine may increase the QTc-prolonging activities of Dofetilide.
DonepezilDonepezil may increase the central neurotoxic activities of Olanzapine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Olanzapine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Olanzapine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine.
EluxadolineOlanzapine may increase the activities of Eluxadoline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Olanzapine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Olanzapine.
EstazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Estazolam.
EthanolOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Olanzapine.
FludiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fludiazepam.
FlunitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Olanzapine.
FlurazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flurazepam.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Olanzapine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine.
GalantamineGalantamine may increase the central neurotoxic activities of Olanzapine.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Olanzapine.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Olanzapine.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Olanzapine.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Olanzapine is combined with Glucagon recombinant.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Olanzapine.
GoserelinOlanzapine may increase the QTc-prolonging activities of Goserelin.
HalazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Halazepam.
HydrocodoneOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olanzapine.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Olanzapine.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Olanzapine.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Olanzapine.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Olanzapine.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Olanzapine.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Olanzapine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olanzapine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Olanzapine.
KetazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketazolam.
LamotrigineLamotrigine may increase the sedative activities of Olanzapine.
LeuprolideOlanzapine may increase the QTc-prolonging activities of Leuprolide.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Olanzapine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine.
LisdexamfetamineOlanzapine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Olanzapine.
LorazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lorazepam.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Olanzapine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Olanzapine.
MequitazineOlanzapine may increase the arrhythmogenic activities of Mequitazine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Olanzapine.
MethamphetamineOlanzapine may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.
MetyrosineOlanzapine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Olanzapine can be decreased when combined with Mexiletine.
MianserinMianserin may increase the anticholinergic activities of Olanzapine.
MidazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Olanzapine.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Olanzapine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
MirabegronThe risk or severity of adverse effects can be increased when Olanzapine is combined with Mirabegron.
MirtazapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Olanzapine.
MorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Olanzapine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Olanzapine.
NitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrazepam.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olanzapine.
OrphenadrineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxazepam.
ParaldehydeOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Olanzapine can be increased when it is combined with Peginterferon alfa-2b.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Olanzapine.
PhendimetrazineOlanzapine may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine.
PhentermineOlanzapine may decrease the stimulatory activities of Phentermine.
Potassium ChlorideOlanzapine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Olanzapine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Olanzapine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Olanzapine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olanzapine.
QuazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Quazepam.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Olanzapine.
RamosetronOlanzapine may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olanzapine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine.
RitonavirThe serum concentration of Olanzapine can be decreased when it is combined with Ritonavir.
RivastigmineRivastigmine may increase the central neurotoxic activities of Olanzapine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Olanzapine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Olanzapine.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Olanzapine.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Olanzapine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Olanzapine.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Olanzapine.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
SulpirideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Olanzapine.
SuvorexantOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine.
TemazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Temazepam.
TeriflunomideThe serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Olanzapine.
ThalidomideOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TiotropiumOlanzapine may increase the anticholinergic activities of Tiotropium.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Olanzapine.
TofisopamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tofisopam.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Olanzapine.
TopiramateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Olanzapine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olanzapine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Olanzapine.
TriazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triazolam.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Olanzapine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olanzapine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Olanzapine.
Valproic AcidThe serum concentration of Olanzapine can be decreased when it is combined with Valproic Acid.
VemurafenibThe serum concentration of Olanzapine can be increased when it is combined with Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Olanzapine.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Olanzapine.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Olanzapine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Olanzapine.
ZolpidemOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA: Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9. [PubMed:14530903 ]
  2. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, Lucignani G, Colombo C, Rizzo G, Velona I, Smeraldi E, Fazio F: Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004 Sep;18(3):355-65. [PubMed:15358979 ]
  3. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ: Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005 Apr;66(4):450-4. [PubMed:15816787 ]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601 ]
  5. Padin JF, Rodriguez MA, Dominguez E, Dopeso-Reyes IG, Buceta M, Cano E, Sotelo E, Brea J, Caruncho HJ, Isabel Cadavid M, Castro M, Isabel Loza M: Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology. 2006 Sep;51(4):923-32. Epub 2006 Aug 14. [PubMed:16905159 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  9. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699 ]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800 ]
  4. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T: In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol. 2007 Aug;21(6):620-7. Epub 2006 Nov 8. [PubMed:17092971 ]
  5. Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, Brown RW: The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci. 2006 Oct;24(7):2075-83. [PubMed:17067304 ]
  6. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006 Mar;163(3):529-31. [PubMed:16513877 ]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R: The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006 Jun;31(6):1310-7. [PubMed:16237394 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006 Feb 14;71(4):521-9. Epub 2005 Dec 5. [PubMed:16336943 ]
  3. Overstreet DH, Knapp DJ, Breese GR: Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res. 2007 Sep;31(9):1473-81. Epub 2007 Jul 11. [PubMed:17624999 ]
  4. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J: No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. Epub 2006 Sep 19. [PubMed:16983399 ]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
  6. Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. [PubMed:16952163 ]
  7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A: The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20(2):101-3. [PubMed:15729086 ]
  3. Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL: Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9- diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J Pharmacol Exp Ther. 2005 Dec;315(3):1265-77. Epub 2005 Sep 1. [PubMed:16141369 ]
  4. Altschuler EL, Kast RE: Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses. 2005;65(1):65-7. [PubMed:15893120 ]
  5. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  6. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  3. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  4. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins.
Gene Name:
HTR5A
Uniprot ID:
P47898
Molecular Weight:
40254.69 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  3. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531 ]
33. D(2L) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
34. D(2S) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 31, 2016 02:12